Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Open accessThe DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The angiotensin receptor-neprilysin inhibitor sacubitril-valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with heart failure and reduced ejection fraction. The effect of angiotensin receptor-neprilysin inhibition in patients with heart failure with preserved ejection fraction is unclear. METHODS: We randomly assigned 4822 patients with New York Heart Association (NYHA) class II to IV heart failure, ejection fraction of 45% or higher, elevated level of natriuretic peptides, and structural heart disease to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or valsartan (target dose, 160 mg twice daily). The primary outcome was a composite of total hospitalizations for heart failure and death from cardiovascular causes. Primary outcome components, secondary outcomes (including NYHA class change, worsening renal function, and change in Kansas City Cardiomyopathy Questionnaire [KCCQ] clinical summary score [scale, 0 to 100, with higher scores indicating fewer symptoms and physical limitations]), and safety were also assessed. RESULTS: There were 894 primary events in 526 patients in the sacubitril-valsartan group and 1009 primary events in 557 patients in the valsartan group (rate ratio, 0.87; 95% confidence interval [CI], 0.75 to 1.01; P = 0.06). The incidence of death from cardiovascular causes was 8.5% in the sacubitril-valsartan group and 8.9% in the valsartan group (hazard ratio, 0.95; 95% CI, 0.79 to 1.16); there were 690 and 797 total hospitalizations for heart failure, respectively (rate ratio, 0.85; 95% CI, 0.72 to 1.00). NYHA class improved in 15.0% of the patients in the sacubitril-valsartan group and in 12.6% of those in the valsartan group (odds ratio, 1.45; 95% CI, 1.13 to 1.86); renal function worsened in 1.4% and 2.7%, respectively (hazard ratio, 0.50; 95% CI, 0.33 to 0.77). The mean change in the KCCQ clinical summary score at 8 months was 1.0 point (95% CI, 0.0 to 2.1) higher in the sacubitril-valsartan group. Patients in the sacubitril-valsartan group had a higher incidence of hypotension and angioedema and a lower incidence of hyperkalemia. Among 12 prespecified subgroups, there was suggestion of heterogeneity with possible benefit with sacubitril-valsartan in patients with lower ejection fraction and in women. CONCLUSIONS: Sacubitril-valsartan did not result in a significantly lower rate of total hospitalizations for heart failure and death from cardiovascular causes among patients with heart failure and an ejection fraction of 45% or higher. (Funded by Novartis; PARAGON-HF ClinicalTrials.gov number, NCT01920711.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Over the past decade, the use of medications that have been demonstrated to be effective in patients with HF with reduced ejection fraction (angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 [SGLT2] inhibitors) has been evaluated in large-scale trials in patients with HF and mildly reduced ejection fraction and patients with HFpE”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the PARAGON-HF trial (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction), neprilysin inhibition reduced the risk of cardiovascular death and total hospitalizations by 13%, improved KCCQ by 1.0 points, and had no overall effect on the EuroQol Visual Analog Scale.3,9”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This level was significantly lower than that in the STEP-HFpEF program (median, ≈470 pg/mL)36 and substantially lower than in other large-scale outcome trials in HFpEF (median 900–1400 pg/mL).3–6”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Self-citationYusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., & Östergren, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14285-7 · Cited by 2,994
Self-citationSpironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Self-citationIrbesartan in patients with heart failure and preserved ejection fraction
Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805450 · Cited by 1,960
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Zile, M. R., Baicu, C. F., & Gaasch, W. H. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032566 · Cited by 1,563
Self-citationThe perindopril in elderly people with chronic heart failure (PEP-CHF) study
Cleland, J. G. F. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl250 · Cited by 1,508
Self-citationSolomon, S. D., Zile, M., Pieske, B., Voors, A., Shah, A., Kraigher-Krainer, E., Shi, V., Bransford, T., Takeuchi, M., Gong, J., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61227-6 · Cited by 1,173
Self-citationPhenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction
Shah, S. J., Katz, D. H., Selvaraj, S., Burke, M. A., Yancy, C. W., Gheorghiade, M., Bonow, R. O., Huang, C.-C., & Deo, R. C. (2015) · Circulation · doi:10.1161/circulationaha.114.010637 · Cited by 1,157
Self-citationSemiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Research works printed but not linked: 1
- Cowling BJ, Hutton JL, Shaw JEH. Joint modeling of event counts and survival times. Appl Stat 2006;55:31-39.
Cited by
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Self-citationHeidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citationMancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206286 · Cited by 2,884
Self-citation2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Authors/Task Force Members:, McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2333 · Cited by 2,171
Self-citationBozkurt, B., Coats, A. J. S., Tsutsui, H., Abdelhamid, C. M., Adamopoulos, S., Albert, N., Anker, S. D., Atherton, J., Böhm, M., Butler, J., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2115 · Cited by 1,665
Self-citation2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Diretrizes Brasileiras de Hipertensão Arterial – 2020
Barroso, W. K. S., Rodrigues, C. I. S., Bortolotto, L. A., Mota-Gomes, M. A., Brandão, A. A., Feitosa, A. D. D. M., Machado, C. A., Poli-de-Figueiredo, C. E., Amodeo, C., Mion, D., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20201238 · Cited by 1,068
Universal Definition and Classification of Heart Failure
Bozkurt, B., Coats, A. J., Tsutsui, H., Abdelhamid, M., Adamopoulos, S., Albert, N., Anker, S. D., Atherton, J., Böhm, M., Butler, J., et al. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.01.022 · Cited by 995
Self-citationHeidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001062 · Cited by 394
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.011 · Cited by 931
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Vaduganathan, M., Claggett, B., Jhund, P. S., Desai, A. S., Henderson, A. D., Lam, C. S. P., Pitt, B., Senni, M., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2407107 · Cited by 893
Self-citationSex differences in heart failure
Lam, C. S. P., Arnott, C., Beale, A. L., Chandramouli, C., Hilfiker-Kleiner, D., Kaye, D. M., Ky, B., Santema, B. T., Sliwa, K., & Voors, A. A. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz835 · Cited by 802
Self-citationHeart Failure With Reduced Ejection Fraction: A Review
Murphy, S. P., Ibrahim, N. E., & Januzzi, J. L. (2020) · JAMA · doi:10.1001/jama.2020.10262 · Cited by 769
Heart Failure With Preserved Ejection Fraction
Borlaug, B. A., Sharma, K., Shah, S. J., & Ho, J. E. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.01.049 · Cited by 742
Self-citationCoronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases
Del Buono, M. G., Montone, R. A., Camilli, M., Carbone, S., Narula, J., Lavie, C. J., Niccoli, G., & Crea, F. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.042 · Cited by 635
“Conversely, sacubitril-valsartan failed to meet a statistical difference on the primary composite endpoint (total HF hospitalizations and cardiovascular death) in the HFpEF population when compared to valsartan(107).”
ResultEvaluation and management of heart failure with preserved ejection fraction
Borlaug, B. A. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0363-2 · Cited by 675
Heart Failure With Preserved Ejection Fraction: A Review
Redfield, M. M., & Borlaug, B. A. (2023) · JAMA · doi:10.1001/jama.2023.2020 · Cited by 662
Self-citationSex differences in type 2 diabetes
Kautzky-Willer, A., Leutner, M., & Harreiter, J. (2023) · Diabetologia · doi:10.1007/s00125-023-05891-x · Cited by 624
Nassif, M. E., Windsor, S. L., Borlaug, B. A., Kitzman, D. W., Shah, S. J., Tang, F., Khariton, Y., Malik, A. O., Khumri, T., Umpierrez, G., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01536-x · Cited by 618
Self-citationGoetze, J. P., Bruneau, B. G., Ramos, H. R., Ogawa, T., de Bold, M. K., & de Bold, A. J. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0381-0 · Cited by 531
Kittleson, M. M., Panjrath, G. S., Amancherla, K., Davis, L. L., Deswal, A., Dixon, D. L., Januzzi, J. L., & Yancy, C. W. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.03.393 · Cited by 554
2020 Clinical practice guidelines for Chronic heart failure
Russian Society of Cardiology (RSC) (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-4083 · Cited by 395
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure
Solomon, S. D., Vaduganathan, M., L. Claggett, B., Packer, M., Zile, M., Swedberg, K., Rouleau, J., A. Pfeffer, M., Desai, A., H. Lund, L., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044586 · Cited by 551
Self-citationHeart failure with mid-range or mildly reduced ejection fraction
Savarese, G., Stolfo, D., Sinagra, G., & Lund, L. H. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00605-5 · Cited by 476
Borlaug, B. A., Jensen, M. D., Kitzman, D. W., Lam, C. S. P., Obokata, M., & Rider, O. J. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac120 · Cited by 450
Self-citationHaemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial
Lindenfeld, J., Zile, M. R., Desai, A. S., Bhatt, K., Ducharme, A., Horstmanshof, D., Krim, S. R., Maisel, A., Mehra, M. R., Paul, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01754-2 · Cited by 432
Self-citationPop-Busui, R., Januzzi, J. L., Bruemmer, D., Butalia, S., Green, J. B., Horton, W. B., Knight, C., Levi, M., Rasouli, N., & Richardson, C. R. (2022) · Diabetes Care · doi:10.2337/dci22-0014 · Cited by 399
Cellular and molecular pathobiology of heart failure with preserved ejection fraction
Mishra, S., & Kass, D. A. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00480-6 · Cited by 417
Shah, S. J., Borlaug, B. A., Kitzman, D. W., McCulloch, A. D., Blaxall, B. C., Agarwal, R., Chirinos, J. A., Collins, S., Deo, R. C., Gladwin, M. T., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.041886 · Cited by 436
Self-citationWriting Committee Members*, Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., et al. (2025) · Hypertension · doi:10.1161/hyp.0000000000000249 · Cited by 310
Women’s Participation in Cardiovascular Clinical Trials From 2010 to 2017
Jin, X., Chandramouli, C., Allocco, B., Gong, E., Lam, C. S. P., & Yan, L. L. (2020) · Circulation · doi:10.1161/circulationaha.119.043594 · Cited by 403
Self-citationPaulus, W. J., & Zile, M. R. (2021) · Circulation Research · doi:10.1161/circresaha.121.318159 · Cited by 393
Self-citationMcMurray, J. J. V., Jackson, A. M., Lam, C. S. P., Redfield, M. M., Anand, I. S., Ge, J., Lefkowitz, M. P., Maggioni, A. P., Martinez, F., Packer, M., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044491 · Cited by 380
Self-citationPacker, M., Butler, J., Zannad, F., Filippatos, G., Ferreira, J. P., Pocock, S. J., Carson, P., Anand, I., Doehner, W., Haass, M., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.056824 · Cited by 354
Self-citationMueller, S., Winzer, E. B., Duvinage, A., Gevaert, A. B., Edelmann, F., Haller, B., Pieske-Kraigher, E., Beckers, P., Bobenko, A., Hommel, J., et al. (2021) · JAMA · doi:10.1001/jama.2020.26812 · Cited by 347
Self-citationSolomon, S. D., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Shah, S. J., Lindholm, D., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2249 · Cited by 326
Self-citationWriting Committee Members*, Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001356 · Cited by 213
Heart failure with preserved ejection fraction: everything the clinician needs to know
Campbell, P., Rutten, F. H., Lee, M. M., Hawkins, N. M., & Petrie, M. C. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02756-3 · Cited by 269
Tomasoni, D., Adamo, M., Lombardi, C. M., & Metra, M. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12555 · Cited by 258
Shah, S. J., Borlaug, B. A., Chung, E. S., Cutlip, D. E., Debonnaire, P., Fail, P. S., Gao, Q., Hasenfuß, G., Kahwash, R., Kaye, D. M., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00016-2 · Cited by 249
Self-citationJones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., Bress, A. P., et al. (2025) · JACC · doi:10.1016/j.jacc.2025.05.007 · Cited by 280
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E., Sato, K., Teramoto, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0002 · Cited by 191
Gliflozins in the Management of Cardiovascular Disease
Braunwald, E. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2115011 · Cited by 266
Brugts, J. J., Radhoe, S. P., Clephas, P. R. D., Aydin, D., van Gent, M. W. F., Szymanski, M. K., Rienstra, M., van den Heuvel, M. H., da Fonseca, C. A., Linssen, G. C. M., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00923-6 · Cited by 248
Shah, A. M., Cikes, M., Prasad, N., Li, G., Getchevski, S., Claggett, B., Rizkala, A., Lukashevich, I., O’Meara, E., Ryan, J. J., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.09.063 · Cited by 252
Self-citationButler, J., Packer, M., Filippatos, G., Ferreira, J. P., Zeller, C., Schnee, J., Brueckmann, M., Pocock, S. J., Zannad, F., & Anker, S. D. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab798 · Cited by 264
Self-citationZile, M. R., O'Meara, E., Claggett, B., Prescott, M. F., Solomon, S. D., Swedberg, K., Packer, M., McMurray, J. J. V., Shi, V., Lefkowitz, M., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.042 · Cited by 254
Self-citation2024 Clinical practice guidelines for Chronic heart failure
Galyavich, A. S., Tereshchenko, S. N., Uskach, T. M., Ageev, F. T., Aronov, D. M., Arutyunov, G. P., Begrambekova, Y. L., Belenkov, Y. N., Boytsov, S. A., Bubnova, M. G., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6162 · Cited by 204
Self-citationPalau, P., Seller, J., Domínguez, E., Sastre, C., Ramón, J. M., de La Espriella, R., Santas, E., Miñana, G., Bodí, V., Sanchis, J., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.073 · Cited by 229
Sex Differences in Heart Failure With Preserved Ejection Fraction
Sotomi, Y., Hikoso, S., Nakatani, D., Mizuno, H., Okada, K., Dohi, T., Kitamura, T., Sunaga, A., Kida, H., Oeun, B., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.018574 · Cited by 221
Everett, B. M., MacFadyen, J. G., Thuren, T., Libby, P., Glynn, R. J., & Ridker, P. M. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.011 · Cited by 220
Multidisciplinary Cardiac Rehabilitation and Long-Term Prognosis in Patients With Heart Failure
Kamiya, K., Sato, Y., Takahashi, T., Tsuchihashi-Makaya, M., Kotooka, N., Ikegame, T., Takura, T., Yamamoto, T., Nagayama, M., Goto, Y., et al. (2020) · Circulation: Heart Failure · doi:10.1161/circheartfailure.119.006798 · Cited by 222
Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies
Omote, K., Verbrugge, F. H., & Borlaug, B. A. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042220-022745 · Cited by 213
Hypertension management in patients with cardiovascular comorbidities
Lauder, L., Mahfoud, F., Azizi, M., Bhatt, D. L., Ewen, S., Kario, K., Parati, G., Rossignol, P., Schlaich, M. P., Teo, K. K., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac395 · Cited by 210
The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications
Kuwahara, K. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107863 · Cited by 207
Spertus, J. A., Fine, J. T., Elliott, P., Ho, C. Y., Olivotto, I., Saberi, S., Li, W., Dolan, C., Reaney, M., Sehnert, A. J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00763-7 · Cited by 220
Abraham, W. T., Lindenfeld, J., Ponikowski, P., Agostoni, P., Butler, J., Desai, A. S., Filippatos, G., Gniot, J., Fu, M., Gullestad, L., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa943 · Cited by 217
Self-citationNicotinamide for the treatment of heart failure with preserved ejection fraction
Abdellatif, M., Trummer-Herbst, V., Koser, F., Durand, S., Adão, R., Vasques-Nóvoa, F., Freundt, J. K., Voglhuber, J., Pricolo, M.-R., Kasa, M., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd7064 · Cited by 212
Anker, S. D., Usman, M. S., Anker, M. S., Butler, J., Böhm, M., Abraham, W. T., Adamo, M., Chopra, V. K., Cicoira, M., Cosentino, F., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2894 · Cited by 201
Self-citationVerbrugge, F. H., Omote, K., Reddy, Y. N. V., Sorimachi, H., Obokata, M., & Borlaug, B. A. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab911 · Cited by 214
The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction
Packer, M. (2025) · JACC · doi:10.1016/j.jacc.2025.06.055 · Cited by 173
Self-citationRole of endothelial dysfunction in heart failure
Zuchi, C., Tritto, I., Carluccio, E., Mattei, C., Cattadori, G., & Ambrosio, G. (2020) · Heart Failure Reviews · doi:10.1007/s10741-019-09881-3 · Cited by 191
Abnormalities of Potassium in Heart Failure
Ferreira, J. P., Butler, J., Rossignol, P., Pitt, B., Anker, S. D., Kosiborod, M., Lund, L. H., Bakris, G. L., Weir, M. R., & Zannad, F. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.04.021 · Cited by 190
Self-citationMeijers, W. C., Bayes‐Genis, A., Mebazaa, A., Bauersachs, J., Cleland, J. G. F., Coats, A. J. S., Januzzi, J. L., Maisel, A. S., McDonald, K., Mueller, T., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2346 · Cited by 186
Self-citationSex- and Gender-Based Pharmacological Response to Drugs
Mauvais-Jarvis, F., Berthold, H. K., Campesi, I., Carrero, J.-J., Dhakal, S., Franconi, F., Gouni-Berthold, I., Heiman, M. L., Kautzky-Willer, A., Klein, S. L., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000206 · Cited by 192
Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
Sweeney, M., Corden, B., & Cook, S. A. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910865 · Cited by 195
“…subgroup analysis of this trial has yielded some interesting results in particular a significant improvement in the primary outcome in women (Solomon et al, 2019) which is particularly intriguing given the high burden of HFpEF in women (Vasan et al, 2018), and this finding may stimulate…”
BackgroundResultGevaert, A. B., Kataria, R., Zannad, F., Sauer, A. J., Damman, K., Sharma, K., Shah, S. J., & Van Spall, H. G. C. (2022) · Heart · doi:10.1136/heartjnl-2021-319605 · Cited by 181
Self-citationSex and Gender Differences in Heart Failure
Regitz-Zagrosek, V. (2020) · International Journal of Heart Failure · doi:10.36628/ijhf.2020.0004 · Cited by 174
Mentz, R. J., Ward, J. H., Hernandez, A. F., Lepage, S., Morrow, D. A., Sarwat, S., Sharma, K., Starling, R. C., Velazquez, E. J., Williamson, K. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.019 · Cited by 178
Self-citationHeart failure with preserved ejection fraction
Hamo, C. E., DeJong, C., Hartshorne-Evans, N., Lund, L. H., Shah, S. J., Solomon, S., & Lam, C. S. P. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00540-y · Cited by 174
Self-citationJCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
Tsutsui, H., Ide, T., Ito, H., Kihara, Y., Kinugawa, K., Kinugawa, S., Makaya, M., Murohara, T., Node, K., Saito, Y., et al. (2021) · Circulation Journal · doi:10.1253/circj.cj-21-0431 · Cited by 183
Sex Differences in Heart Failure
Lala, A., TAYAL, U., HAMO, C. E., YOUMANS, Q., AL-KHATIB, S. M., BOZKURT, B., DAVIS, M. B., JANUZZI, J., MENTZ, R., SAUER, A., et al. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.10.006 · Cited by 179
Mc Causland, F. R., Lefkowitz, M. P., Claggett, B., Anavekar, N. S., Senni, M., Gori, M., Jhund, P. S., McGrath, M. M., Packer, M., Shi, V., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.047643 · Cited by 179
Self-citationEpidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes
Park, J. J. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0282 · Cited by 171
“Until now, no drugs in HFrEF improved survival in HFpEF [89-92], although some may reduce the HHF.”
BackgroundPacker, M., Lam, C. S. P., Lund, L. H., Maurer, M. S., & Borlaug, B. A. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1902 · Cited by 185
Self-citationSorimachi, H., Obokata, M., Takahashi, N., Reddy, Y. N. V., Jain, C. C., Verbrugge, F. H., Koepp, K. E., Khosla, S., Jensen, M. D., & Borlaug, B. A. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa823 · Cited by 183
Diagnosis of Heart Failure With Preserved Ejection Fraction Among Patients With Unexplained Dyspnea
Reddy, Y. N. V., Kaye, D. M., Handoko, M. L., van de Bovenkamp, A. A., Tedford, R. J., Keck, C., Andersen, M. J., Sharma, K., Trivedi, R. K., Carter, R. E., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.1916 · Cited by 170
Self-citationMenopause-Related Estrogen Decrease and the Pathogenesis of HFpEF
Sabbatini, A. R., & Kararigas, G. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.12.049 · Cited by 173
“Notably, the latest data show that inhibition of the angiotensin receptor and neprilysin did not result in a significantly lower rate of total hospitalizations for HF and death from cardiovascular causes among patients with HFpEF (42).”
BackgroundMaconi, G., Parente, F., Bollani, S., Cesana, B. M., & Porro, G. B. (1996) · PubMed · Cited by 177
Pieske, B., Wachter, R., Shah, S. J., Baldridge, A., Szeczoedy, P., Ibram, G., Shi, V., Zhao, Z., Cowie, M. R., PARALLAX Investigators and Committee members, et al. (2021) · JAMA · doi:10.1001/jama.2021.18463 · Cited by 163
Self-citationMineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis
Jhund, P. S., Talebi, A., Henderson, A. D., Claggett, B. L., Vaduganathan, M., Desai, A. S., Lam, C. S. P., Pitt, B., Senni, M., Shah, S. J., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01733-1 · Cited by 190
“11 The lack of effect of all of these treatments on all-cause death in patients with a higher ejection fraction could be due to the much larger proportion of non-cardiovascular deaths in this group compared with people with lower ejection fraction, 12 with non-cardiovascular deaths unlikely to be…”
BackgroundSelf-citationThe New Biology of Diabetic Kidney Disease—Mechanisms and Therapeutic Implications
Lytvyn, Y., Bjornstad, P., van Raalte, D. H., Heerspink, H. L., & Cherney, D. Z. I. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz010 · Cited by 165
Cardoso, R. N., Graffunder, F. P., Ternes, C. M. P., Fernandes, A. D. F., Rocha, A. V., Fernandes, G. C., & Bhatt, D. L. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100933 · Cited by 184
“Specifically, we performed pre-specified analyses of the composite of cardiovascular mortality or HF hospitalizations/urgent visits in the following subgroups: (1) male; (2) female; (3) age 65 years old; (4) age <65 years old; (5) White race; (6) Black race; (7) estimated glomerular filtration rate (eGFR) 60 mL/min/1¢…”
ResultInfluentialCrosstalk between the renin–angiotensin, complement and kallikrein–kinin systems in inflammation
Bekassy, Z., Lopatko Fagerström, I., Bader, M., & Karpman, D. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-021-00634-8 · Cited by 167
Bachtiger, P., Petri, C. F., Scott, F. E., Ri Park, S., Kelshiker, M. A., Sahemey, H. K., Dumea, B., Alquero, R., Padam, P. S., Hatrick, I. R., et al. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(21)00256-9 · Cited by 167
JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
Tsutsui, H., Ide, T., Ito, H., Kihara, Y., Kinugawa, K., Kinugawa, S., Makaya, M., Murohara, T., Node, K., Saito, Y., et al. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.04.023 · Cited by 158
Frailty and heart failure: State‐of‐the‐art review
Talha, K. M., Pandey, A., Fudim, M., Butler, J., Anker, S. D., & Khan, M. S. (2023) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13306 · Cited by 181
“The PARAGON-HF trial evaluated the efficacy of sacubitril– valsartan in patients with HF and LVEF > 40% and did not find a significant reduction in the primary endpoint of HF hospitalizations and cardiovascular death.(85) A post hoc analysis was performed in 4795 patients stratified by frailty status using the deficit…”
Heart failure with preserved ejection fraction: New approaches to diagnosis and management
Upadhya, B., & Kitzman, D. W. (2019) · Clinical Cardiology · doi:10.1002/clc.23321 · Cited by 168
Docherty, K. F., Vaduganathan, M., Solomon, S. D., & McMurray, J. J. V. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.06.020 · Cited by 157
Self-citationRosch, S., Kresoja, K., Besler, C., Fengler, K., Schöber, A. R., von Roeder, M., Lücke, C., Gutberlet, M., Klingel, K., Thiele, H., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.059280 · Cited by 163
Jackson, A. M., Jhund, P. S., Anand, I. S., Düngen, H.-D., Lam, C. S. P., Lefkowitz, M. P., Linssen, G., Lund, L. H., Maggioni, A. P., Pfeffer, M. A., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab499 · Cited by 156
Self-citationClassification of Heart Failure According to Ejection Fraction
Lam, C. S. P., & Solomon, S. D. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.04.070 · Cited by 174
Self-citationCausland, F. R. M., Claggett, B. L., Vaduganathan, M., Desai, A. S., Jhund, P. S., de Boer, R. A., Docherty, K. F., Fang, J. C., Hernandez, A. F., Inzucchi, S. E., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.4210 · Cited by 162
Self-citationSex-Related Differences in Heart Failure With Preserved Ejection Fraction
Dewan, P., Rørth, R., Raparelli, V., Campbell, R. T., Shen, L., Jhund, P. S., Petrie, M. C., Anand, I. S., Carson, P. E., Desai, A. S., et al. (2019) · Circulation Heart Failure · doi:10.1161/circheartfailure.119.006539 · Cited by 151
Self-citationPeikert, A., Martínez, F. A., Vaduganathan, M., Claggett, B. L., Kulac, I. J., Desai, A. S., Jhund, P. S., de Boer, R. A., DeMets, D. L., Hernandez, A. F., et al. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.122.010080 · Cited by 171
“8,15,16 Consistent with previous randomized trials, patient characteristics varied between age categories, with no significant differences observed between patients randomized to dapagliflozin compared with those randomized to placebo.”
Self-citationWithaar, C., Lam, C. S. P., Schiattarella, G. G., de Boer, R. A., & Meems, L. M. G. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab389 · Cited by 150
Self-citationIncreasing Participation of Women in Cardiovascular Trials
Cho, L., Vest, A. R., O’Donoghue, M. L., Ogunniyi, M. O., Sarma, A. A., Denby, K. J., Lau, E. S., Poole, J. E., Lindley, K. J., & Mehran, R. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.06.022 · Cited by 153
Metadata
- Authors
- Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., Redfield, M. M., Rouleau, J. L., van Veldhuisen, D. J., Zannad, F., Zile, M. R., Desai, A. S., Claggett, B., Jhund, P. S., Boytsov, S. A., Comin-Colet, J., Cleland, J., Düngen, H.-D., Goncalvesova, E., Katova, T., Kerr Saraiva, J. F., Lelonek, M., Merkely, B., Senni, M., Shah, S. J., Zhou, J., Rizkala, A. R., Gong, J., Shi, V. C., & Lefkowitz, M. P.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston (S.D.S., M.A.P., A.S.D., B.C.); the British Heart Foundation Cardiovascular Research Centre (J.J.V.M., P.S.J.) and the Robertson Centre for Biostatistics and Clinical Trials, Institute of Health and Well-being (J.C.), University of Glasgow, Glasgow, and the National Heart and Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College, London (J.C.) — all in the United Kingdom; University of...
- ORCID
- Solomon, Scott D.
- McMurray, John J.V.
- Anand, Inder S.
- Ge, Junbo
- Lam, Carolyn S.P.
- Maggioni, Aldo P.
- Packer, Milton
- Pfeffer, Marc A.
- Pieske, Burkert
- Redfield, Margaret M.
- Rouleau, Jean L.
- Zannad, Faiez
- Zile, Michael R.
- Desai, Akshay S.
- Claggett, Brian
- Jhund, Pardeep S.
- Boytsov, Sergey A.
- Cleland, John
- Düngen, Hans-Dirk
- Lelonek, Małgorzata
- Senni, Michele
- Shah, Sanjiv J.
- Zhou, Jingmin
- Rizkala, Adel R.
- Gong, Jianjian
- Shi, Victor C.
- Lefkowitz, Martin P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-10-24
- Volume
- 381
- Issue
- 17
- Pages
- 1609-1620
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2971294569
- Cited by
- 2,430
- References
- 25
- Citations by year
- 2026: 258 · 2025: 296 · 2024: 338 · 2023: 361 · 2022: 414 · 2021: 385 · 2020: 318 · 2019: 55
- FWCI
- 211.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Research Bank (Australian Catholic University) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Novartis
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- sacubitril/valsartan, valsartan, angiotensin receptor-neprilysin inhibition, heart failure with preserved ejection fraction, heart failure hospitalization, cardiovascular mortality, NYHA functional class, renal function, Kansas City Cardiomyopathy Questionnaire, natriuretic peptides, structural heart disease, drug safety, adverse events, anemia of chronic kidney disease, hyperkalemia
- MeSH terms
- Valsartan, Aged, Aminobutyrates, Angioedema, Biphenyl Compounds, Cardiovascular Diseases, Double-Blind Method, Drug Combinations, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Hypotension, Male, Middle Aged, Quality of Life, Sex Factors, Stroke Volume, Tetrazoles, Neprilysin, Single-Blind Method, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.